Talk to us

About us

Immuneed is a privately-held contract research organization specializing in immunology and preclinical drug development.
We offer in-house services to address important questions related to the safety and function of biopharmaceuticals. At Immuneed, our goal is to contribute to safer drugs for humans all over the world. We are driven because we know people’s lives are at stake. That realization underpins everything we do, reminding us why we continuously work hard to deliver benefits for patients and create value for our shareholders.

Our story

Immuneed was founded in 2014 and initially focused on the development of a novel immunotherapy for cancer. As the evaluation of this therapeutic vaccine grew more complex, we developed a proprietary platform to characterize the drug and predict outcomes in a clinical setting, thereby reducing animal studies and giving early indications of the effect in humans. In 2018, the vaccine project was acquired by the Norwegian pharmaceutical company Ultimovacs.

Today we are fully focused on developing Immuneed’s platform and associated services, which benefit biotech and pharmaceutical companies across Europe. Our platform, which is based on circulating, fresh human blood, is the only commercially available system that can monitor immune-mediated reactions in real-time – thereby linking preclinical data to clinical reality. By addressing important questions related to drug safety and immunology, we cut our customers’ costs and add value to drug development projects.

Board of directors

Our board of directors is responsible for corporate governance, overseeing risk and setting Immuneed’s strategy and policies, as well as monitoring our progress according to the annual business plan. The board represents the interests of our shareholders and is accountable for the proper conduct and growth of Immuneed’s business. Below you will find the board’s members, along with a short biography.

Members of the board

Camilla Huse Bondesson, Chair
Camilla has an MBA and more than 25 years of experience of working with biotech, diagnostics and medical device companies, Camilla Huse Bondesson has held managerial and operational positions within sales, product and marketing management. She is experienced as a business coach for life science companies, and her key areas of expertise include commercialization strategies, market positioning, and business development.
Sara Mangsbo, PhD, Founder
Sara Mangsbo, PhD and founder of Immueed and Associate Professor in immunology at Uppsala University. She has over 11 years of experience in the field of immunotherapy both in the pre-clinical and clinical space. Sara Mangsbo has also held a position at AstraZeneca as Brand Lead of Immuno-oncology. In addition to her role as CSO at Immuneed, Sara Mangsbo is a principal investigator and senior associate lecturer at Uppsala University where she heads a team that studies novel immunotherapeutics for the treatment of cancer.
Håkan Englund
Håkan Englund is private investor in Immuneed and the former Executive Vice President at Phadia AB. He has held several leading and executive positions within Pharmacia Diagnostics and Pharmacia Biotech. Håkan Englund is a board member of several Medtech and life science companies and is presently on the board of Arocell AB, Apotekssamariten AB, Antrad Medical AB, and Sensidose AB.
Charlotte Leife
Charlotte has an MBA in business and administration and chemistry. She has more than 25 years of leadership from biotech and pharma. During 2018-2020 she was the CEO of Immuneed and before that she was Vice President for Biogen in the US and in the Nordic countries.
Fredrik Lehmann
Fredrik has a PhD in Medicinal Chemistry and is a serial biotech entrepreneur having founded a handful of companies. Currently he holds positions as CEO of EpiEndo and EVP research and CMC at Oncopeptides. Fredrik has almost 20 years of experience from working in research and management positions in life science.
Fredrik Frejd
Fredrik Frejd has a PhD in Pharmaceutical Sciences from the Swiss federal institute of technology (ETH), is adjunct professor at Uppsala University with special focus on development of minimized tumor targeting agents, and is a member of the scientific advisory board at the center for Molecular Bioengineering at the Technical University of Dresden. He is CSO of Affibody, a company developing a novel class protein drugs to treat autoinflammatory disorders and cancer. Fredrik has more than 20 years of experience in life science research and protein drug development

Selected customers

I'm interested

If you want to know more about Immuneed and our services – whether you are a potential client, partner, employee or student – we would be happy to hear from you.